LGM
RNAC icon

Logos Global Management’s Cartesian Therapeutics RNAC Stock Holding History

Logos Global Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-90,000
Closed -$2.43M – 66
2024
Q2 		$2.43M Buy
+90,000
New +$2.15M 0.2% 53
2020
Q2 		– Sell
-37,062
Closed -$2.68M – 58
2020
Q1 		$2.68M Buy
+37,062
New +$3.58M 1.02% 33

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Logos Global Management's RNAC Position: Q3 2024 in Review

Logos Global Management sold out of Cartesian Therapeutics (RNAC) in Q3 2024, closing a stake of 90,000 shares — an estimated $2.43M sold.

Logos Global Management first reported a position in RNAC in Q1 2020 and held it in 2 quarters. The position peaked at $2.68M in Q1 2020. 64 funds tracked by Wall St. Rank hold RNAC as of Q3 2024.

  • Logos Global Management reported no remaining Cartesian Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Logos Global Management sold 90,000 Cartesian Therapeutics shares in Q3 2024, an estimated $2.43M.
  • Logos Global Management first reported a position in Cartesian Therapeutics in Q1 2020 and held it in 2 quarters.
  • Logos Global Management's Cartesian Therapeutics position peaked at $2.68M in Q1 2020.
  • 64 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2024.

Based on Logos Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.